Financings in Brief: Laser Industries, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Laser Industries, Inc.: Plans to redeem all of its outstanding 8% convertible subordinated debentures due Sept. 15, 2006 on Sept. 16, 1996 "at a redemption price of 100% of the principal amount thereof, plus accrued interest to the redemption date," the firm states. The Tel Aviv, Israel medical laser firm issued $20 mil. of the debentures in September 1986 for debt repayment and working capital. About $2.6 mil. of the debentures are outstanding...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.